As recently reported by Zhao and colleagues, patients with a lower plasma KRAS c34G > T (pG12C) allele frequency and a lower tumor burden at baseline tend to be what are called exceptional responders (i.e., complete or partial response lasting more than 12 months) when treated with sotorasib [177]. This evidence concerns the gene KRAS and neoplasm.